Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Colorcon
McKinsey
Baxter
McKesson

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR BUSPIRONE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Buspirone Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00021528 ↗ Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Completed National Institute of Mental Health (NIMH) Phase 4 2001-07-01 STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated
NCT00029692 ↗ Effects of Ginseng and Ginkgo on Drug Disposition in Man Completed National Center for Complementary and Integrative Health (NCCIH) Phase 2 2002-03-01 This study will assess the effects of ginseng and ginkgo on 1) cognitive function, 2) enzymes that process drugs, and 3) enzymes that may help prevent cancer.
NCT00053846 ↗ Buspirone in Reducing Shortness of Breath in Patients With Cancer Completed National Cancer Institute (NCI) Phase 2/Phase 3 2002-11-01 RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy. PURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing shortness of breath in patients who are undergoing chemotherapy for cancer.
NCT00053846 ↗ Buspirone in Reducing Shortness of Breath in Patients With Cancer Completed University of Rochester Phase 2/Phase 3 2002-11-01 RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy. PURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing shortness of breath in patients who are undergoing chemotherapy for cancer.
NCT00086112 ↗ Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy. Completed Janssen, LP Phase 3 1969-12-31 The purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Buspirone Hydrochloride

Condition Name

Condition Name for Buspirone Hydrochloride
Intervention Trials
Anxiety 5
Major Depressive Disorder 4
Depression 4
Spinal Cord Injuries 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Buspirone Hydrochloride
Intervention Trials
Disease 17
Anxiety Disorders 11
Depressive Disorder 7
Depression 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Buspirone Hydrochloride

Trials by Country

Trials by Country for Buspirone Hydrochloride
Location Trials
United States 104
China 7
Canada 6
France 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Buspirone Hydrochloride
Location Trials
Massachusetts 13
Texas 9
Ohio 7
New York 7
Pennsylvania 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Buspirone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Buspirone Hydrochloride
Clinical Trial Phase Trials
Phase 4 16
Phase 3 7
Phase 2/Phase 3 2
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Buspirone Hydrochloride
Clinical Trial Phase Trials
Completed 44
Recruiting 8
Terminated 6
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Buspirone Hydrochloride

Sponsor Name

Sponsor Name for Buspirone Hydrochloride
Sponsor Trials
National Institute on Drug Abuse (NIDA) 8
Massachusetts General Hospital 8
Medical University of South Carolina 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Buspirone Hydrochloride
Sponsor Trials
Other 67
NIH 18
Industry 16
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Baxter
Harvard Business School
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.